pirfenidone has been researched along with Cardiovascular Stroke in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aimo, A; Bayes-Genis, A; Burchielli, S; Emdin, M; Galvez-Monton, C; Iborra-Egea, O; Martini, N; Panichella, G; Passino, C | 1 |
| Fu, Y; Guo, Y; Liao, B; Liu, L; Ma, H; Ma, L; Qian, H; Qin, C; Shen, J; Shi, J | 1 |
| Aimo, A; Aquaro, GD; Barison, A; Burchielli, S; Emdin, M; Masotti, S; Modena, M; Musetti, V; Passino, C; Pucci, A; Terlizzi, D | 1 |
| Adamo, L; Bajpai, G; Barger, PM; Bhattacharya, D; Jiang, W; Kovacs, A; Mann, DL; Matkovich, SJ; Rocha-Resende, C; Schilling, JD; Staloch, LJ; Weinheimer, CJ | 1 |
| Gao, Y; Han, R; He, J; Kang, L; Li, C; Li, Y; Tian, J; Wang, J | 1 |
| Ding, C; Marcus, GM; Nguyen, DT; Olgin, JE; Wilson, E | 1 |
1 trial(s) available for pirfenidone and Cardiovascular Stroke
| Article | Year |
|---|---|
Effects of pirfenidone on scar size and ventricular remodeling after myocardial infarction: a preclinical study.
Topics: Animals; Cicatrix; Fibrosis; Humans; Male; Myocardial Infarction; Rats; Rats, Wistar; Ventricular Remodeling | 2023 |
5 other study(ies) available for pirfenidone and Cardiovascular Stroke
| Article | Year |
|---|---|
Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis.
Topics: Animals; Computational Biology; Fibrosis; Myocardial Infarction; Myocardium; Pyridones; Swine; Ventricular Function, Left; Ventricular Remodeling | 2022 |
Alleviation of cardiac fibrosis using acellular peritoneal matrix-loaded pirfenidone nanodroplets after myocardial infarction in rats.
Topics: Animals; Collagen; Fibrosis; Myocardial Infarction; Myocardium; Pyridones; Rats | 2022 |
Modulation of subsets of cardiac B lymphocytes improves cardiac function after acute injury.
Topics: Animals; B-Lymphocyte Subsets; Diphtheria Toxin; Disease Models, Animal; Female; Heart Ventricles; Humans; Lipopolysaccharides; Lymphocyte Activation; Lymphocyte Depletion; Mice; Myocardial Infarction; Myocardium; Pyridones; Reperfusion Injury; Ventricular Remodeling | 2018 |
Pirfenidone controls the feedback loop of the AT1R/p38 MAPK/renin-angiotensin system axis by regulating liver X receptor-α in myocardial infarction-induced cardiac fibrosis.
Topics: Angiotensin II; Animals; Cardiomegaly; Collagen Type I; Collagen Type III; Feedback, Physiological; Fibrosis; Hemodynamics; Hydroxyproline; Liver X Receptors; Male; Myocardial Infarction; Myocardium; p38 Mitogen-Activated Protein Kinases; Peptidyl-Dipeptidase A; Phosphorylation; Proto-Oncogene Mas; Proto-Oncogene Proteins; Pyridones; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, G-Protein-Coupled; Renin-Angiotensin System; Signal Transduction; Systole; Ventricular Dysfunction | 2017 |
Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias.
Topics: Animals; Echocardiography; Electrophysiologic Techniques, Cardiac; Fibrosis; Heart Conduction System; Heart Ventricles; Male; Myocardial Infarction; Neural Conduction; Pyridones; Rats; Rats, Sprague-Dawley; Tachycardia, Ventricular; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Ventricular Function, Left; Ventricular Remodeling; Voltage-Sensitive Dye Imaging | 2010 |